Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : JT-09
Therapeutic Area : Dermatology
Study Phase : Preclinical
Sponsor : Titan Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Public Offering
Titan Pharma Completes Debt Settlement with Molteni and Horizon; Acquisition of JT-09
Details : As a result of the debt settlement with Molteni and Horizon, there are no liens remaining on any of Titan's assets. With the net proceeds from recent public the company is well positioned to progress preclinical development of its ProNeura-based pipeline...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
November 02, 2020
Lead Product(s) : JT-09
Therapeutic Area : Dermatology
Highest Development Status : Preclinical
Sponsor : Titan Pharmaceuticals Inc
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Buprenorphine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Recipient : Accord healthcare
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Accord will commercialize Sixmo®▼ (buprenorphine implant), an opioid agonist therapy treatment, delivered through a first-of-its-kind implant, placed under the skin for six-months.
Product Name : Sixmo
Product Type : Controlled Substance
Upfront Cash : Undisclosed
September 14, 2020
Lead Product(s) : Buprenorphine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Recipient : Accord healthcare
Deal Size : Undisclosed
Deal Type : Agreement
PEctin Rapid Fentanyl Efficacy Clinical Trial For pAin at Swallowing Undergoing radioTherapy
Details : Fentanyl is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 11, 2013
Reset All
